Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19
Author
Edmonds, SterlingMacGregor, Andrea
Doll, Agnieszka
Vural, Ipek Eren
Graham, Janice
Fierlbeck, Katherine
Lexchin, Joel
Doshi, Peter
Herder, Matthew
Date
2020-11-19Journal
Journal of Law and the BiosciencesPublisher
Oxford University PressType
Article
Metadata
Show full item recordIdentifier to cite or link to this item
http://hdl.handle.net/10713/14655ae974a485f413a2113503eed53cd6c53
10.1093/jlb/lsaa083
Scopus Count
Related articles
- A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation.
- Authors: Lexchin J, Mintzes B
- Issue date: 2014
- Trust and transparency in times of crisis: Results from an online survey during the first wave (April 2020) of the COVID-19 epidemic in the UK.
- Authors: Enria L, Waterlow N, Rogers NT, Brindle H, Lal S, Eggo RM, Lees S, Roberts CH
- Issue date: 2021
- Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19.
- Authors: Lexchin J, Graham J, Herder M, Jefferson T, Lemmens T
- Issue date: 2021 Jan
- Toward a jurisprudence of drug regulation.
- Authors: Herder M
- Issue date: 2014 Summer
- A real-time policy dashboard can aid global transparency in the response to coronavirus disease 2019.
- Authors: Head MG
- Issue date: 2020 Sep 1